As a result of the high mutation burden of MSI CRC, the tumor cells present multiple neoantigens (i.e. PD-L1)—in line with this theory and several previous studies46,76,84, our data document a significant PD-L1 overexpression in MMR-deficient CRC tumor cells. This evidence concerns the gene CD274 and neoplasm.